Headline News

Laparoscopy may offer perioperative advantages to laparotomy and may be an acceptable alternative for some women with ovarian cancer, but systematic review and meta-analysis findings are limited by inclusion of only observational studies.

CHICAGO — In the BRAIN-AF trial, daily rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack, compared with placebo, among younger patients with atrial fibrillation and low stroke risk.

BOSTON — Encouraging health-seeking behaviors could expedite recovery for patients with allergic rhinitis, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

WASHINGTON — A focus on patient follow-up, standardized medication adherence and barriers assessments can reduce racial and ethnic disparities in juvenile idiopathic arthritis, according to a speaker at ACR Convergence 2024.

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.

BOSTON — Community engagement can help stock inhaler programs for underserved rural schools succeed, according to two posters presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

During assessments of episodic memory, processing speed, and inhibition and attention, children with vs. without asthma had poorer scores, according to results published in JAMA Network Open.

Among adult smokers who moved from smoking cigarettes to e-cigarettes exclusively, wheeze resolution went up, but this was not the case if they moved to dual use, according to results published in Nicotine and Tobacco Research.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.